Personal profile
Fingerprint
Dive into the research topics where Tim Rowland is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19 A Dose-Escalating, Randomized Controlled Phase Ib Study
the AGILE CST-6 Study Group, Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., Hale, C., Shaw, V., Kelly, C., Lyon, R., Gibney, J., Dhamani, K., Irwin, M., Enever, Y., Tetlow, M., Wood, W., Reynolds, H., Chiong, J. & Osanlou, O. & 13 others, , 18 Mar 2026, In: Clinical Pharmacology and Therapeutics. 119, 6, p. 1650-1661 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus) -
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS-CoV-2 infection
Challenger, E., Else, L., Dickinson, L., Rowland, T., Wood, W., Hale, C., Lyon, R., Reynolds, H., Chiong, J., Owen, A., FitzGerald, R., Fletcher, T. & Khoo, S., 3 Sept 2025, In: British Journal of Clinical Pharmacology. 91, S1, p. 22 1 p.Research output: Contribution to journal › Meeting Abstract
Open Access -
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.
Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., Rowland, T., Fletcher, T., Khoo, S. & Else, L., 21 Apr 2024, In: Journal of Pharmaceutical and Biomedical Analysis. 245, p. 116155 116155.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus) -
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., Hadjiyiannakis, D., Walker, L., Lyon, R., Shaw, V., Mozgunov, P., Periselneris, J., Woods, C., Bullock, K., Hale, C., Reynolds, H., Downs, N., Ewings, S., Buadi, A. & Cameron, D. & 30 others, , 1 Feb 2023, In: The Lancet Infectious Diseases. 23, 2, p. 183-195 13 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile72 Citations (Scopus) -
Therapeutics for treating mpox in humans
Fox, T., Gould, S., Princy, N., Rowland, T., Lutje, V. & Kuehn, R., 14 Mar 2023, In: Cochrane Database of Systematic Reviews. 2023, 3, p. CD015769 CD015769.Research output: Contribution to journal › Review article › peer-review
Open AccessFile43 Citations (Scopus)